查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1451768

2024-2032 年痴呆症药物市场（依适应症、药物类别、配销通路和地区划分）

Dementia Drugs Market by Indication, Drug Class, Distribution Channel, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 147 Pages | 商品交期: 2-3个工作天内

价格

2023年全球失智症药物市场规模达183亿美元。展望未来， IMARC Group预计到2032年市场规模将达到346亿美元，2024-2032年复合年增长率（CAGR）为7.09%。由于全球人口老化、人们对痴呆症相关疾病的认识和诊断不断提高，以及为发现阿兹海默症和其他形式痴呆症的有效治疗方法而进行的持续研究和开发工作，该市场正在经历稳定增长。

痴呆症药物市场分析：

市场成长与规模：在痴呆症相关疾病（尤其是阿兹海默症）盛行率不断上升的推动下，全球痴呆症药物市场正在经历显着增长。由于全球人口老化以及对控制认知能力下降和改善患者生活品质的有效治疗的需求不断增长，市场规模正在扩大。

技术进步：神经影像技术、生物标记识别和精准医学的进步有助于早期诊断和个人化治疗计划。远距医疗和数位健康平台正在加强对痴呆症患者和照护者的远端监控和支援。

产业应用：痴呆药物市场主要集中在药品上，包括胆碱酯酶抑制剂和NMDA受体拮抗剂。非药物介入措施，例如认知刺激疗法和行为管理策略，也变得越来越重要。

地理趋势：由于痴呆症盛行率较高且研究基础设施强大，北美和欧洲拥有完善的市场。由于意识的增强和医疗保健投资的增加，亚太地区的新兴市场正在经历快速成长。

竞争格局：市场的特点是竞争激烈，主要参与者专注于创新、併购（M&A）以及扩大全球足迹。製药公司也在研发方面投入大量资金，以获得竞争优势。

挑战与机会：挑战包括药物开发的高成本、监管障碍以及长期临床试验的需要。机会在于早期诊断、新药发现和非药物介入。

未来展望：痴呆症药物市场可望持续成长，重点在于疾病缓解疗法和个人化医疗。神经影像学、生物标记识别和远距医疗的进步预计将塑造痴呆症护理的未来。

痴呆症药物市场趋势：

人口老化

痴呆症药物市场的主要驱动力之一是全球人口老化。随着人们寿命的延长，痴呆症等与年龄相关的疾病的发生率自然会增加。这种人口结构的变化导致对痴呆症相关医疗保健服务和药物的需求增加。世界卫生组织报告称，到2050年，60岁及以上的人口数量预计将增加一倍。老年人口的增加很可能导致痴呆症患病率激增，从而刺激对有效的痴呆症药物的需求。

技术进步

痴呆症药物市场也受到药物研究和开发的重大进步的推动。随着对痴呆症背后的神经生物学机制有了更好的了解，製药公司越来越多地投资开发更有效、更有针对性的药物。这些进展包括探索新的治疗标靶，例如淀粉样蛋白斑块和 tau 蛋白，它们被认为在阿兹海默症（最常见的痴呆症）的发展中发挥着至关重要的作用。此外，神经影像技术的进步，例如正子断层扫描（PET）和磁振造影（MRI），可以更准确地诊断和监测痴呆症相关疾病。此外，生物标记识别和基因研究正在推动精准医学方法的发展。药物发现、临床试验设计和远距医疗的技术创新也提高了痴呆症药物开发和病患照护的效率。

提高认识和早期诊断

人们对痴呆症及其症状的认识不断增强，从而促进了早期诊断和治疗。公共卫生运动和教育措施正在提高人们对痴呆症早期症状的认识，鼓励人们儘早寻求医疗建议。早期诊断对于有效管理痴呆症至关重要，因为它可以及时干预并减缓疾病的进展。这种意识的不断增强，加上诊断技术的改进，正在推动对痴呆症药物的需求。

医疗保健支出增加

全球医疗保健支出的增加是推动痴呆症药物市场的另一个因素。政府和医疗机构正在分配更多资源来管理和治疗慢性病，包括失智症。增加的资金支持研究、药物开发和改善治疗选择。它也反映出对加强医疗基础设施和服务的更广泛承诺，从而促进更好地管理痴呆症症状和进展。此外，政府、医疗保健组织和倡导团体越来越认识到解决痴呆症的紧迫性。这种认可正在推动研究资金的成长，并创造有利于製药创新的环境。

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球痴呆药物市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依迹象

  • 路易氏体失智症
    • 市场走向
    • 市场预测
  • 帕金森氏症 痴呆症
    • 市场走向
    • 市场预测
  • 阿兹海默氏症
    • 市场走向
    • 市场预测
  • 血管性失智症
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 7 章：市场区隔：依药物类别

  • 胆碱酯酶抑制剂
    • 市场走向
    • 市场预测
  • NMDA拮抗剂及其组合药物
    • 市场走向
    • 市场预测

第 8 章：市场区隔：按配销通路

  • 零售药局
    • 市场走向
    • 市场预测
  • 医院药房
    • 市场走向
    • 市场预测
  • 网路药局
    • 市场走向
    • 市场预测

第 9 章：市场区隔：按地区

  • 北美洲
    • 美国
      • 市场走向
      • 市场预测
    • 加拿大
      • 市场走向
      • 市场预测
  • 亚太
    • 中国
      • 市场走向
      • 市场预测
    • 日本
      • 市场走向
      • 市场预测
    • 印度
      • 市场走向
      • 市场预测
    • 韩国
      • 市场走向
      • 市场预测
    • 澳洲
      • 市场走向
      • 市场预测
    • 印尼
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 欧洲
    • 德国
      • 市场走向
      • 市场预测
    • 法国
      • 市场走向
      • 市场预测
    • 英国
      • 市场走向
      • 市场预测
    • 义大利
      • 市场走向
      • 市场预测
    • 西班牙
      • 市场走向
      • 市场预测
    • 俄罗斯
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 拉丁美洲
    • 巴西
      • 市场走向
      • 市场预测
    • 墨西哥
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 中东和非洲
    • 市场走向
    • 市场细分：按国家/地区
    • 市场预测

第 10 章：驱动因素、限制与机会

  • 概述
  • 司机
  • 限制
  • 机会

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbvie Inc.
    • Apotex Inc.
    • Biogen Inc.
    • Eisai Co. Ltd.
    • Johnson & Johnson
    • Merck & Co. Inc.
Product Code: SR112024A7490

The global dementia drugs market reached US$ 18.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 34.6 Billion by 2032, exhibiting a growth rate (CAGR) of 7.09% during 2024-2032. The market is experiencing steady growth driven by aging global population, increasing awareness and diagnosis of dementia-related conditions, and ongoing research and development efforts to discover effective treatments for Alzheimer's disease and other forms of dementia.

Dementia Drugs Market Analysis:

Market Growth and Size: The global dementia drugs market is experiencing significant growth, driven by the increasing prevalence of dementia-related conditions, particularly Alzheimer's disease. Market size is expanding due to the aging global population and the rising demand for effective treatments to manage cognitive decline and improve the quality of life for patients.

Technological Advancements: Advances in neuroimaging technologies, biomarker identification, and precision medicine are aiding in early diagnosis and personalized treatment plans. Telemedicine and digital health platforms are enhancing remote monitoring and support for dementia patients and caregivers.

Industry Applications: The dementia drugs market is primarily focused on pharmaceuticals, including cholinesterase inhibitors and NMDA receptor antagonists. Non-pharmacological interventions, such as cognitive stimulation therapies and behavioral management strategies, are also gaining importance.

Geographical Trends: North America and Europe have well-established markets due to a higher prevalence of dementia and strong research infrastructure. Emerging markets in Asia-Pacific are experiencing rapid growth due to increasing awareness and healthcare investments.

Competitive Landscape: The market is characterized by intense competition with key players focusing on innovation, mergers and acquisitions (M&A), and expanding their global footprint. Pharmaceutical companies are also investing heavily in research and development to gain a competitive edge.

Challenges and Opportunities: Challenges include the high cost of drug development, regulatory hurdles, and the need for long-term clinical trials. Opportunities lie in early diagnosis, novel drug discovery, and non-pharmacological interventions.

Future Outlook: The dementia drugs market is poised for continued growth with a focus on disease-modifying therapies and personalized medicine. Advances in neuroimaging, biomarker identification, and telemedicine are expected to shape the future of dementia care.

Dementia Drugs Market Trends:

Ageing population

One of the primary drivers of the dementia drugs market is the aging global population. As people live longer, the incidence of age-related diseases like dementia naturally increases. This demographic shift results in a higher demand for dementia-related healthcare services and medications. The World Health Organization reports that the number of people aged 60 years and older is expected to double by 2050. This increase in the elderly population is likely to lead to a surge in the prevalence of dementia, thereby fueling the demand for effective dementia drugs.

Technological Advancements

The dementia drugs market is also driven by significant advancements in pharmaceutical research and development. With a better understanding of the neurobiological mechanisms behind dementia, pharmaceutical companies are increasingly investing in the development of more effective and targeted drugs. These advancements include the exploration of new therapeutic targets, such as amyloid plaques and tau proteins, which are believed to play a crucial role in the development of Alzheimer's disease, the most common form of dementia. Besides, advances in neuroimaging technologies, such as positron emission tomography (PET) and magnetic resonance imaging (MRI), enable more accurate diagnosis and monitoring of dementia-related conditions. Additionally, biomarker identification and genetic research are driving the development of precision medicine approaches. Technological innovations in drug discovery, clinical trial design, and telemedicine are also enhancing the efficiency of dementia drug development and patient care.

Increasing awareness and early diagnosis

There is a growing awareness about dementia and its symptoms, leading to earlier diagnosis and treatment. Public health campaigns and educational initiatives are increasing awareness of dementia's early signs, encouraging people to seek medical advice sooner. Early diagnosis is crucial in managing dementia effectively, as it allows for timely intervention and slows the progression of the disease. This growing awareness, coupled with improvements in diagnostic techniques, is driving the demand for dementia drugs.

Rising healthcare expenditure

Increasing healthcare expenditure globally is another factor boosting the dementia drugs market. Governments and healthcare organizations are allocating more resources to manage and treat chronic conditions, including dementia. This increased funding supports research, drug development, and improved access to treatment options. It also reflects a broader commitment to enhancing healthcare infrastructure and services, thereby facilitating better management of dementia symptoms and progression. Besides, governments, healthcare organizations, and advocacy groups are increasingly recognizing the urgency of addressing dementia. This recognition is driving funding for research and creating an environment conducive to pharmaceutical innovation.

Dementia Drugs Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on indication, drug class, and distribution channel.

Breakup by Indication:

Lewy Body Dementia

Parkinson's Disease Dementia

Alzheimer's Disease

Vascular Dementia

Others

Alzheimer's disease accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the dementia drugs market based on the indication. This includes Lewy body dementia, Parkinson's disease dementia, Alzheimer's disease, vascular dementia, and others. According to the report, Alzheimer's disease represented the largest segment.

Breakup by Drug Class:

Cholinesterase Inhibitors

NMDA Antagonists and its Combination Drugs

Cholinesterase inhibitors holds the largest share in the industry

A detailed breakup and analysis of the dementia drugs market based on the drug class has also been provided in the report. This includes cholinesterase inhibitors and NMDA antagonists and its combination drugs. According to the report, cholinesterase inhibitors accounted for the largest market share.

Breakup by Distribution Channel:

Retail Pharmacies

Hospital Pharmacies

Online Pharmacies

Hospital pharmacies represents the leading market segment

The report has provided a detailed breakup and analysis of the dementia drugs market based on the distribution channel. This includes retail pharmacies, hospital pharmacies, and online pharmacies. According to the report, hospital pharmacies represented the largest segment.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest dementia drugs market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Abbvie Inc.

Apotex Inc.

Biogen Inc.

Eisai Co. Ltd.

Johnson & Johnson

Merck & Co. Inc.

Key Questions Answered in This Report:

  • How has the global dementia drugs market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global dementia drugs market?
  • What is the impact of each driver, restraint, and opportunity on the global dementia drugs market?
  • What are the key regional markets?
  • Which countries represent the most attractive dementia drugs market?
  • What is the breakup of the market based on the indication?
  • Which is the most attractive indication in the dementia drugs market?
  • What is the breakup of the market based on the drug class?
  • Which is the most attractive drug class in the dementia drugs market?
  • What is the breakup of the market based on the distribution channel?
  • Which is the most attractive distribution channel in the dementia drugs market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global dementia drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Dementia Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Indication

  • 6.1 Lewy Body Dementia
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Parkinson's Disease Dementia
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Alzheimer's Disease
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Vascular Dementia
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Cholinesterase Inhibitors
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 NMDA Antagonists and its Combination Drugs
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Retail Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Hospital Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Pharmacies
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbvie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Apotex Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 SWOT Analysis
    • 14.3.3 Biogen Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Eisai Co. Ltd.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Johnson & Johnson
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Merck & Co. Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

  • Figure 1: Global: Dementia Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Dementia Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Dementia Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Dementia Drugs Market: Breakup by Indication (in %), 2023
  • Figure 5: Global: Dementia Drugs Market: Breakup by Drug Class (in %), 2023
  • Figure 6: Global: Dementia Drugs Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Dementia Drugs Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Dementia Drugs (Lewy Body Dementia) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Dementia Drugs (Lewy Body Dementia) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Dementia Drugs (Parkinson's Disease Dementia) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Dementia Drugs (Parkinson's Disease Dementia) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Dementia Drugs (Alzheimer's Disease) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Dementia Drugs (Alzheimer's Disease) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Dementia Drugs (Vascular Dementia) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Dementia Drugs (Vascular Dementia) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Dementia Drugs (Other Indications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Dementia Drugs (Other Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Dementia Drugs (Cholinesterase Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Dementia Drugs (Cholinesterase Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Dementia Drugs (NMDA Antagonists and its Combination Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Dementia Drugs (NMDA Antagonists and its Combination Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Dementia Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Dementia Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Dementia Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Dementia Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Dementia Drugs (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Dementia Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: North America: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: North America: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: United States: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: United States: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Canada: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Canada: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Asia-Pacific: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Asia-Pacific: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: China: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: China: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Japan: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Japan: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: India: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: India: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: South Korea: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: South Korea: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Australia: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Australia: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Indonesia: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Indonesia: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Others: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Others: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Europe: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Europe: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Germany: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Germany: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: France: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: France: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: United Kingdom: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: United Kingdom: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Italy: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Italy: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Spain: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Spain: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Russia: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Russia: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Others: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Others: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Latin America: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Latin America: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Brazil: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Brazil: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Mexico: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Mexico: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Others: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Others: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Middle East and Africa: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Middle East and Africa: Dementia Drugs Market: Breakup by Country (in %), 2023
  • Figure 76: Middle East and Africa: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Global: Dementia Drugs Industry: Drivers, Restraints, and Opportunities
  • Figure 78: Global: Dementia Drugs Industry: Value Chain Analysis
  • Figure 79: Global: Dementia Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Dementia Drugs Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Dementia Drugs Market Forecast: Breakup by Indication (in Million US$), 2024-2032
  • Table 3: Global: Dementia Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 4: Global: Dementia Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 5: Global: Dementia Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Dementia Drugs Market: Competitive Structure
  • Table 7: Global: Dementia Drugs Market: Key Players